128 related articles for article (PubMed ID: 36478146)
1. Risk and prognosis of secondary breast cancer after radiation therapy for non-Hodgkin lymphoma: a massive population-based analysis.
Lv X; Yue P; Zhou F
Clin Transl Oncol; 2023 May; 25(5):1307-1314. PubMed ID: 36478146
[TBL] [Abstract][Full Text] [Related]
2. Risk and Prognosis of Secondary Bladder Cancer After Radiation Therapy for Rectal Cancer: A Large Population-Based Cohort Study.
Guan X; Wei R; Yang R; Lu Z; Liu E; Zhao Z; Chen H; Yang M; Liu Z; Jiang Z; Wang X
Front Oncol; 2020; 10():586401. PubMed ID: 33569344
[TBL] [Abstract][Full Text] [Related]
3. Risk and prognosis of secondary bladder cancer after radiation therapy for pelvic cancer.
Li S; Wei R; Yu G; Liu H; Chen T; Guan X; Wang X; Jiang Z
Front Oncol; 2022; 12():982792. PubMed ID: 36091158
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of secondary bladder cancer after radiation therapy for endometrial cancer.
Wen L; Zhong G; Ren M
Sci Rep; 2022 Jan; 12(1):1032. PubMed ID: 35058550
[TBL] [Abstract][Full Text] [Related]
5. Risk and prognosis of secondary bladder cancer after post-operative radiotherapy for gynecological cancer.
Wen L; Zhong G; Zhang Y; Zhong M
Bosn J Basic Med Sci; 2022 Jun; 22(3):471-480. PubMed ID: 34716699
[TBL] [Abstract][Full Text] [Related]
6. Secondary Breast Cancer Risk by Radiation Volume in Women With Hodgkin Lymphoma.
Conway JL; Connors JM; Tyldesley S; Savage KJ; Campbell BA; Zheng YY; Hamm J; Pickles T
Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):35-41. PubMed ID: 27979454
[TBL] [Abstract][Full Text] [Related]
7. Age-related risk for second breast cancer and gynecological malignant neoplasms after differentiated thyroid cancer.
Zhao X; Yang G; Zhang W; Dong Q; Yang Q
Endocrine; 2022 May; 76(2):385-394. PubMed ID: 35122212
[TBL] [Abstract][Full Text] [Related]
8. Association of Radioiodine for Differentiated Thyroid Cancer and Second Breast Cancer in Female Adolescent and Young Adult.
Zhao X; Chen M; Qi X; Zhu H; Yang G; Guo Y; Dong Q; Yang Q
Front Endocrinol (Lausanne); 2021; 12():805194. PubMed ID: 35154006
[TBL] [Abstract][Full Text] [Related]
9. Superior survival for breast-conserving therapy over mastectomy in patients with breast cancer: A population-based SEER database analysis across 30 years.
Ke S; Wang W; Li B; Feng X; Yan D; Liu J
Front Oncol; 2022; 12():1032063. PubMed ID: 36686746
[TBL] [Abstract][Full Text] [Related]
10. Incidence and survival of second primary non-Hodgkin lymphoma: A Surveillance, Epidemiology, and End Results-based cohort study.
Yu N; Zhang W; Zhong X; Song X; Li W
PLoS One; 2024; 19(3):e0300330. PubMed ID: 38466704
[TBL] [Abstract][Full Text] [Related]
11. Risk and prognosis of second corpus uteri cancer after radiation therapy for pelvic cancer: A population-based analysis.
Yu G; Wei R; Li S; Wang Y; Liu H; Chen T; Guan X; Wang X; Jiang Z
Front Oncol; 2022; 12():957608. PubMed ID: 36249002
[TBL] [Abstract][Full Text] [Related]
12. Risk and prognosis of secondary esophagus cancer after radiotherapy for breast cancer.
Sun Q; Chen Y; Li T; Ni B; Zhu X; Xu B; Li J
Sci Rep; 2023 Mar; 13(1):3968. PubMed ID: 36894590
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic radiation for lymphoma and risk of second primary malignant mesothelioma.
Chang ET; Lau EC; Mowat FS; Teta MJ
Cancer Causes Control; 2017 Sep; 28(9):971-979. PubMed ID: 28755241
[TBL] [Abstract][Full Text] [Related]
14. Mortality After Invasive Second Breast Cancers Following Prior Radiotherapy for DCIS.
Li PC; Zhang Z; Cronin AM; Punglia RS
J Natl Compr Canc Netw; 2019 Nov; 17(11):1367-1371. PubMed ID: 31693983
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular mortality among patients with non-Hodgkin lymphoma: Differences according to lymphoma subtype.
Abuamsha H; Kadri AN; Hernandez AV
Hematol Oncol; 2019 Aug; 37(3):261-269. PubMed ID: 30916804
[TBL] [Abstract][Full Text] [Related]
16. Risk of second breast cancer in female Hodgkin's lymphoma survivors: a meta-analysis.
Ibrahim EM; Abouelkhair KM; Kazkaz GA; Elmasri OA; Al-Foheidi M
BMC Cancer; 2012 May; 12():197. PubMed ID: 22639888
[TBL] [Abstract][Full Text] [Related]
17. Therapy-related Acute Myeloid Leukemia in Non-Hodgkin Lymphoma Survivors: Risk, Survival Outcomes and Prognostic Factor Analysis.
Joshi U; Bhattarai A; Gaire S; Budhathoki P; Agrawal V; Subedi R; Poudyal BS; Dhakal P; Sham R; Bhatt VR
Hematol Oncol Stem Cell Ther; 2023 Jul; 17(1):79-87. PubMed ID: 37581464
[TBL] [Abstract][Full Text] [Related]
18. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma.
Tward JD; Wendland MM; Shrieve DC; Szabo A; Gaffney DK
Cancer; 2006 Jul; 107(1):108-15. PubMed ID: 16708354
[TBL] [Abstract][Full Text] [Related]
19. Causes of death and effect of non-cancer-specific death on rates of overall survival in adult classic Hodgkin lymphoma: a populated-based competing risk analysis.
Gao J; Chen Y; Wu P; Wang F; Tao H; Shen Q; Wang S; Gong S; Zhang X; Zhou Z; Song X; Jia Y
BMC Cancer; 2021 Aug; 21(1):955. PubMed ID: 34433456
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and Determinants of Survival for Primary Intestinal Non-Hodgkin Lymphoma: A Population-Based Study.
Singh V; Gor D; Gupta V; Jacob A; Du D; Eltoukhy H; Meghal T
World J Oncol; 2022 Aug; 13(4):159-171. PubMed ID: 36128593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
